Rock Springs Capital Management
$2.0B 13F equity value
117 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Rock Springs Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 1,105,210 | $207M | 10.1% |
| TVTX | TRAVERE THERAPEUTICS INC | 2,179,069 | $124M | 6.0% |
| LLY | ELI LILLY & CO | 98,700 | $118M | 5.8% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 174,999 | $94M | 4.6% |
| MIRM | MIRUM PHARMACEUTICALS INC | 798,145 | $93M | 4.6% |
| RYTM | RHYTHM PHARMACEUTICALS INC | 692,598 | $77M | 3.8% |
| KYMR | KYMERA THERAPEUTICS INC | 453,156 | $52M | 2.5% |
| ARGX | ARGENX SE | 52,750 | $49M | 2.4% |
| ASND | ASCENDIS PHARMA A/S | 168,750 | $45M | 2.2% |
| XENE | XENON PHARMACEUTICALS INC | 683,907 | $41M | 2.0% |
Track Rock Springs Capital Management's 13F portfolio: $2.0B in reported holdings, 117 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}